Bullish Moving Averages
15
Bearish Moving Averages
1
Back Stocks profile
Stock analysis tool for investors
Performance
Open Price
24.70Prev. Close
24.6700Volume
8000.00Value
197360.00Fundamentals
Market Cap
11.90
Price to Earnings
0.00
Price to Book Value
1.70
Dividend Yield
0.00
PE to Growth
0.00
Op Revenue TTM
0.00
Net Profit TTM
0.00
Cash From Operating Activity
-1.26
Return on Equity %
0.66
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
100
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
24.67
PIVOT
First Resistance
24.67
Second Resistance
24.67
Third Resistance
24.67
First Support
24.67
Second Support
24.67
Third Support
24.67
Relative Strength Index
61.39
Money Flow Index
64.73
MACD
2.73
MACD Signal
3
Average True Range
1.38
Average Directional Index
25.95
Rate of Change (21)
128.43
Rate of Change (125)
267.66
Commodity Channel Index
39.5
Williams %R
-66.3
BETA
1 Month
-3.82
3 Month
1.5
1 Year
3 Year
PRICE CHANGE ANALYSIS
↓ %
1 Week
Low
High
↓ 0%
1 Month
Low
High
24.67
24.67
↑ 4.98%
3 Months
Low
High
24.67
24.67
↓ -8.97%
6 Months
Low
High
23.5
25.75
↑ 137.21%
1 Year
Low
High
7.5
28.49
04 Jul 2024
Ganga Pharmaceuticals Ltd - 539680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended June 30, 2024.
17 Jun 2024
Ganga Pharmaceuticals Ltd - 539680 - Submission Of Revised Audited Financial Results For The Half And Financial Year Ended March 31, 2024.
Submission of Revised Audited Financial Results for the half and financial year ended March31, 2024
29 May 2024
Ganga Pharmaceuticals Ltd - 539680 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Non-Applicability of Annual Secretarial Compliance Report for the year ended March 31, 2024.
16 May 2024
Ganga Pharmaceuticals Ltd - 539680 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Financial Year ended March 31, 2024
16 May 2024
Ganga Pharmaceuticals Ltd - 539680 - Statement Of Deviation For March 31, 2024
Statement of Deviation or Variation for March 31, 2024
16 May 2024
Ganga Pharmaceuticals Ltd - 539680 - Board Meeting Outcome for Audited Financial Results Of The Company For The Half And Financial Year Ended On March 31, 2024.
Audited Financial Results of the Company for the half and financial year ended on March 31, 2024.
16 May 2024
Ganga Pharmaceuticals Ltd - 539680 - Audited Financial Results Of The Company For The Half And Financial Year Ended On March 31, 2024.
Audited Financial Results of the Company for the half and Financial year ended on March 31, 2024
06 May 2024
Ganga Pharmaceuticals Ltd - 539680 - Board Meeting Intimation for To Inter Alia, Consider And Approve The Audited Financial Results Of The Company For The Half And Financial Year Ended March 31, 2024.
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve the Audited Financial Results of the Company for the half and Financial Year ended March 31, 2024.
25 Apr 2024
Ganga Pharmaceuticals Ltd - 539680 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGanga Pharmaceuticals Ltd 2CIN NO.L99999MH1989PLC053392 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1.36 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Priti Kothari Bhaiya Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Anagh B Sharma Designation: Chief Financial Officer EmailId: [email protected] Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
11 Apr 2024
Ganga Pharmaceuticals Ltd - 539680 - Submission Of Certificate Under Clause 40(10) Of SEBI (LODR) Regulation, 2015 For The Year Ended On March 31, 2024
Submission of Certificate under clause 40(10) of SEBI (LODR) Regulation, 2015 for the year ended on March 31, 2024
